Crofelemer Improves Diarrhea in People with HIV

Crofelemer (brand name Fulyzaq) was well-tolerated and significantly reduced non-infectious diarrhea among HIV positive people taking antiretroviral drugs, according to a study published in the November-December 2013 issue of HIV Clinical Trials.


Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.alt

CD4 T Memory Stem Cells Act as HIV Reservoir

A specific type of long-lived CD4 T-cells known as T memory stem cells continue to harbor high levels of HIV DNA despite suppressive antiretroviral therapy, and may constitute one of the main reservoirs that make the virus so difficult to eradicate, according to a reports in the January 12, 2014, online edition of Nature Medicine.


Low CD4 Count Raises Risk of Heart Attack, Bone Loss

HIV positive people whose CD4 T-cell count falls below 200 cells/mm3 are at greater risk for myocardial infarction, though the heart attack rate is not elevated for people with counts of 500 cells/mm3 or more, researchers recently reported. Another study found that people with low CD4 counts have a higher likelihood of bone loss after starting antiretroviral therapy (ART).


Researchers Find New Toxic Weapon Against HIV in Mouse Study

Researchers have developed a targeted cytotoxin, or cell-toxic agent, to kill HIV that persists in various tissue reservoirs despite antiretroviral therapy, according to a report in the January 9, 2014, issue of PLoS Pathogens.


Dolutegravir for HIV and Sofosbuvir for Hepatitis C Approved in Europe

The European Commission this week approved 2 important new drugs, ViiV Healthcare's HIV integrase inhibitor dolutegravir (brand name Tivicay) and Gilead Science's nucleotide hepatitis C virus polymerase inhibitor sofosbuvir (Sovaldi).


Studies Shed Light on Sexual Transmission of HIV Among Young Gay Men

Young men who have sex with men tend to have higher HIV viral load compared with heterosexuals, contributing to a greater likelihood of transmission, according to a recent report. Another recent study offers more information on the risk of HIV transmission associated with specific sexual activities in the absence of antiretroviral treatment.